The global 3D bioprinting market (henceforth referred to as the market studied) was valued at USD 586.13 million in 2019, and it is expected to reach USD 1949.94 million by 2025, registering a CAGR of 21.91%, during the period of 2020-2025. The global 3D bioprinting market is expected to experience growth, owing to its revolutionary breakthrough in healthcare and pharmaceutical industries.
– 3D bioprinting is an emerging field represented by various biologically applied deposition and assembling systems, which include direct writing, photolithography, microstamping, extrusion, laser writing, stereolithography, electro-printing, microfluidics, and inkjet deposition. Healthcare is one of the major markets where 3D bioprinting has been bringing a seismic change. This is majorly because of the increasing investments in healthcare applications, such as model and organ prototyping and production throughout the globe, and growing innovations in healthcare through 3D printing.
– The primarily growing bioprinting applications include 3D bioprinted tissue and hair follicles, as they are very beneficial to cosmetics companies, especially in Europe, where animal testing for cosmetics was banned in 2013. For a cosmetic company, the advantage will be the ability to economically and ethically test products (i.e., not on animals) across varying skin types, for more accurate results.
Click Here to Download Sample Report >> https://www.sdki.jp/sample-request-90081
Key Market Trends
Drug Testing to Hold Major Share
– 3D bioprinters are of the highest importance for drug testing and clinical trial applications expected to drastically reduce the need for animal trials (therefore not only being ethically beneficial but also being cost-effective).
– Traditionally, clinical trials for new drug development involved testing on animals with artificially induced affected tissues. With the advent of 3D bioprinting, drug developers may be able to address the complications associated with human clinical trials of new drugs, by identifying them in a short period (since these can be tested with human-like 3D printed tissues). Thus, they are expected to reduce the losses incurred during late-stage failures.
– The regulatory agency of the United States Food and Drug Administration has already started to consider integrating alternatives for drug safety and efficacy assessment, providing scope for the market. Companies, like Organovo (US-based) were instrumental in the development of 3D bioprinter able to develop liver and kidney tissue for drug discovery applications.
– In April 2019, NIBIB-funded researchers at the University of Minnesota (UMN) created a new, dynamic 3D Bioprinted tumor model in a laboratory dish to screen anticancer drugs and study the spread of cancer and primary site tumor growth.
3D Bioprinting Market
Screenless Display Market
Force Sensors Market
Shunt Reactor Market
Near Field Communication Market
Grow Lights Market
Rubber Testing Equipment Market
Navigation System Market
Wireless Sensors Market
Image Sensors Market